Elsevier

Biological Psychiatry

Volume 23, Issue 4, 15 February 1988, Pages 326-334
Biological Psychiatry

Article
Increased level of salivary prostaglandins in patients with major depression

https://doi.org/10.1016/0006-3223(88)90283-1Get rights and content

Abstract

We quantified the amounts of salivary prostaglandin (PG) D2, PGE2, and PGF by radioimmunoassay in 32 patients with major depressive disorder, 16 patients with minor depressive disorder, 24 patients with neurotic disorders (panic, generalized anxiety, phobic, somatization, and obsessive compulsive), and 28 healthy controls. In the saliva of patients with major depressive disorder, the concentrations of immunoreactive PCs (PGD2, 385 ± 71 pg/ml; PGE2, 498 ± 105 pg/ml; PGF, 444 ± 100 pg/ml) were significantly higher than those of the healthy controls (PGD2, 129 ± 18 pg/ml; PGE2, 207 ± 25 pg/ml; PGF, 164 ± 17 pg/ml). On the other hand, the salivary concentrations of immunoreactive PCs from patients with minor depressive disorder or neurotic disorders were comparable to those of the controls. These results suggest that the level of salivary PCs may be an indicator of major depressive disorder.

References (46)

  • S Narumiya et al.

    Prostaglandin D2 in rat brain, spinal cord and pituitary: Basal level and regional distribution

    Life Sci

    (1982)
  • T Ohkubo et al.

    Effect of prostaglandin D2 on pain and inflammation

    Jpn J Pharmacol

    (1983)
  • WS Powell

    Rapid extraction of oxygenated metabolites of arachidonic acid from biological samples using octadecylsilyl silica

    Prostaglandins

    (1980)
  • B Rigas et al.

    Human salivary eicosanoids: Circadian variation

    Biochem Biophys Res Commun

    (1983)
  • R Ueno et al.

    Prostaglandin D2 induced sleep when microinjected into the preoptic area of conscious rats

    Biochem Biophys Res Commun

    (1982)
  • T Watanabe et al.

    Characterization of the biosynthetic pathway of prostaglandin D2 in human platelet-rich plasma

    J Biol Chem

    (1982)
  • T Watanabe et al.

    NADP-linked 15-hydroxyprostaglandin dehydrogenase for prostaglandin D2 in human blood platelets

    Arch Biochem Biophys

    (1982)
  • F Coceani

    Prostaglandins and the central nervous system

    Arch Intern Med

    (1974)
  • U Förstermann et al.

    Effects of intracerebroventricular administration of prostaglandin D2 on behaviour, blood pressure and body temperature as compared to prostaglandin E2 and F

    Psychopharmacology

    (1983)
  • G Gottlieb et al.

    Salivation in depressed patients

    Arch Gen Psychiatry

    (1961)
  • GA Hedge et al.

    The effects of prostaglandins on ACTH secretion

    Endocrinology

    (1972)
  • MG Horning et al.

    Use of saliva in therapeutic drug monitoring

    Clin Chem

    (1977)
  • S Inoué et al.

    Differential sleeppromoting effects of five sleep substances nocturnally infused in unrestrained rats

  • Cited by (123)

    • Metabolic/inflammatory/vascular comorbidity in psychiatric disorders; soluble epoxide hydrolase (sEH) as a possible new target

      2018, Neuroscience and Biobehavioral Reviews
      Citation Excerpt :

      The extensive variability in the measurement of cytokine levels within and between laboratories (Noble et al., 2008), and substantial heterogeneity between studies comparing cytokines between patients to controls (Kohler et al., 2017), or comparing patients to themselves pre- vs. post-treatment (Hannestad et al., 2011), suggests suboptimal utility as diagnostic or prognostic biomarkers. Considerably less work has examined the possibility of lipid metabolic biomarkers, although prostaglandins measured quantitatively have shown promise (Calabrese et al., 1986; Nishino et al., 1989; Ohishi et al., 1988). There exists a clear need to identify specific markers of inflammation in depressive disorders, the sources of heterogeneity in related inflammatory pathways, and the underlying causes.

    View all citing articles on Scopus
    View full text